NYSE - Nasdaq Real Time Price USD

Merck & Co., Inc. (MRK)

Compare
125.85 -0.07 (-0.06%)
At close: July 25 at 4:00 PM EDT
125.85 0.00 (0.00%)
After hours: July 25 at 7:55 PM EDT
Loading Chart for MRK
DELL
  • Previous Close 125.92
  • Open 126.03
  • Bid 125.54 x 1000
  • Ask 125.87 x 800
  • Day's Range 125.72 - 127.85
  • 52 Week Range 99.14 - 134.63
  • Volume 6,033,370
  • Avg. Volume 8,269,249
  • Market Cap (intraday) 318.932B
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) 141.40
  • EPS (TTM) 0.89
  • Earnings Date Jul 30, 2024
  • Forward Dividend & Yield 3.08 (2.45%)
  • Ex-Dividend Date Sep 16, 2024
  • 1y Target Est 143.28

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

www.merck.com

70,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MRK

View More

Performance Overview: MRK

Trailing total returns as of 7/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MRK
16.86%
S&P 500
13.20%

1-Year Return

MRK
18.76%
S&P 500
18.54%

3-Year Return

MRK
77.57%
S&P 500
22.38%

5-Year Return

MRK
87.80%
S&P 500
78.81%

Compare To: MRK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MRK

View More

Valuation Measures

Annual
As of 7/24/2024
  • Market Cap

    318.93B

  • Enterprise Value

    347.53B

  • Trailing P/E

    139.91

  • Forward P/E

    14.62

  • PEG Ratio (5yr expected)

    0.10

  • Price/Sales (ttm)

    5.22

  • Price/Book (mrq)

    7.90

  • Enterprise Value/Revenue

    5.66

  • Enterprise Value/EBITDA

    38.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.76%

  • Return on Assets (ttm)

    10.26%

  • Return on Equity (ttm)

    5.31%

  • Revenue (ttm)

    61.4B

  • Net Income Avi to Common (ttm)

    2.31B

  • Diluted EPS (ttm)

    0.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.62B

  • Total Debt/Equity (mrq)

    84.65%

  • Levered Free Cash Flow (ttm)

    9.59B

Research Analysis: MRK

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

124.50
143.28 Average
125.85 Current
155.00 High
 

Company Insights: MRK

Research Reports: MRK

View More
  • The Argus Min Vol Model Portfolio

    Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.

     
  • The Argus Min Vol Model Portfolio

    Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.

     
  • Argus Quick Note: Weekly Stock List for 06/17/2024: Focus List Changes

    Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.

     
  • Argus Adjusts Sector Ratings

    We have reviewed our recommended sector allocations this month, and based on the analysis we have adjusted our current sector Over-Weight, Under-Weight, and Market-Weight recommendations. Our multi-factor model includes a performance-ranking system, which assigns points for monthly, quarterly, and YTD sector performance versus the benchmark S&P 500; current sector P/E versus five-year P/E, with points awarded for discount to S&P 500 current versus five-year P/E delta; two-year earnings growth, with points awarded for exceeding the benchmark average and for EPS acceleration; relative performance to the sector group average; sector conviction, meaning BUY rating percentage per sector versus total Argus BUY-rating percentage; and PEG ratio, with points awarded or subtracted based on sector PEG ratios below or above the group average. Our process yielded 42 total points, for an average sector score of 3.8. To earn an Over-Weight designation, sectors had to score five points or above; for Market-Weight, three or four points; and for Under-Weight, two points or below. Our current Over-Weight sectors are Healthcare, Communication Services, Financial, and Information Technology. Our current Market-Weight sectors are Consumer Discretionary, Energy (raised from Under-Weight), Industrials, Real Estate and Utilities. Our Under-Weight sectors are Materials and Consumer Staples. We suggest that advisors and investors leverage this consistent and comprehensive process to adjust sector weightings within their diversified equity portfolios, with a primary focus on the largest sectors.

     

People Also Watch